Santen Pharmaceuticals said today it picked up glaucoma-treating Microshunt developer InnFocus for $225 million, plus additional consideration upon reaching certain milestones. The Microshunt system is designed to help reduce pressure within the eye in patients with moderate and late stage open angle glaucoma, and is intended to be an alternative to traditional glaucoma surgery. “The InnFocus […]
Innfocus touts 3-year MicroShunt data
InnFocus said Wednesday that results from a 3-year trial of its MicroShunt drainage system designed to treat glaucoma patients reported a significant reduction in intraocular pressure and the use of glaucoma medication. Results from the study were published in the Journal of Glaucoma, the company said. “These results show not only the potential effectiveness but […]
InnFocus closes $34m Series C for glaucoma MicroShunt
InnFocus said it closed a $33.9 million Series C round for the upcoming clinical trial of its MicroShunt device for treating glaucoma. Last month InnFocus won the FDA’s approval to add an additional 412 patients to its clinical trial ahead of a bid for pre-market approval. The last phase of the study is slated to begin in […]
InnFocus wins FDA clearance for glaucoma trial expansion
InnFocus said today it won FDA approval to expand a clinical study of its Microshunt glaucoma drainage system to cover trabeculectomy. The Microshunt system is designed to help reduce pressure within the eye in patients with moderate and late stage open angle glaucoma, and is intended to be an alternative to traditional glaucoma surgery, the […]
AdvaMed taps LifeScience Alley’s Mandle to lead state medtech alliance | Personnel Moves
AdvaMed said it named Shaye Mandle, CEO of Minnesota’s LifeScience Alley trade association, as chairman of its State Medical Technology Alliance. “The medical technology industry is a hallmark of U.S. innovation represented by a community of people dedicated to improving and saving lives. Now more than ever, medical technology has the opportunity to help deliver […]
Glaucoma treatment: InFocus meets enrollment goal on MicroShunt clinical trial
InnFocus has reached its goal of enrolling 75 patients in a Phase I clinical study for its MicroShunt glaucoma eye-drainage implant.
The device is used to help reduce pressure within the eye in patients with glaucoma. The product is intended to be an alternative to traditional glaucoma surgery.
